For a long time, it was believed that apoptosis and necrosis were the main pathways for cell death, but a growing body of research has shown that there are other pathways. Among these, necroptosis, a regulatory caspase-independent, programmed cell death pathway, is supposed to be of importance in the pathogenesis of many diseases. The mechanism of regulating, inducing and blocking necroptosis is a complex process that involves expression and regulation of a series of molecules including receptor interacting protein kinase 1 (RIPK1), RIPK3, and mixed lineage kinase like protein. By blocking or downregulating expression of key molecules in the necroptotic pathway, intestinal inflammation can be affected to some extent. In this paper, we introduce the concept of necroptosis, its main pathway, and its impact on the pathogenesis of inflammatory bowel disease (IBD) and other intestinal diseases, to explore new drug targets for intestinal diseases, including IBD.
INTRODUCTION
The balance between cell death, proliferation and differentiation focuses on the maintenance of ho meostasis and normal development. Cell death has long been thought to occur primarily in two ways: apoptosis and necrosis. The former refers to caspase dependent programmed cell death. Due to the quick phagocytosis and degradation of apoptosomes by phagocytes [1] , apoptosis is normally considered to be an immune silent cellular activity. The latter is mainly characterized by destruction of cell membrane integrity, release of a large number of intracellular components, and induction of inflammatory reactions in surround ing tissues [2] . However, more and more studies have proved that cell death is not only caused by apoptosis or necrosis. In 2005, Degterev et al [3] reported a new method of cell death: necroptosis. This new cell death pathway has similar morphological features to necro sis, but the mechanism of the regulation is caspase independent programmed cell death. With the use of caspase inhibition, necroptosis can be triggered by the combination of death receptor and ligand.
TUMOR NECROSIS FACTOR-α PATHWAY AND OTHER PATHWAYS FOR NECROPTOSIS
Although studies have shown that there may be multiple pathways involved in necroptosis, the tumor necrosis factor (TNF)αmediating pathway is considered to be the most widely researched one. It can be activated by the combination of TNFα and TNF receptor 1 (TNFR1).
Since the downstream of TNFα and TNFR1 pathways involves a variety of molecules that participate in several physiological processes including cell survival, apop tosis, necrosis, necroptosis, and inflammatory factor production, the combination can mediate different cell physiological processes through the formation of diverse compounds corresponding to specific physiological or pathological conditions. 746 WJCC|www.wjgnet.com
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Formation of Complex Ⅰ
The combination of TNFα and TNFR1 can raise TNFα receptor associated death domain protein (TRADD), receptor interacting protein kinase (RIPK)1, TNFR associated factor 2, cellular inhibitors of apoptosis (cIAP1 or cIAP2) and linear ubiquitin chain assembly complex to form Complex Ⅰ. Complex Ⅰ can activate the mitogenactivated protein kinase (MAPK) pathway and nuclear factor (NF)κB pathway by collecting TGF-TAK1-TAB complex and IKK1-IKK2-NEMO complex, then activating the proinflammatory pathway to avoid cell death [4] .
Formation of Complex Ⅱ a
Complex Ⅱa is composed of TRADD, Fasassociated dea th domain (FADD) and caspase8, which forms when Complex Ⅰ is unstable. Complex Ⅱa mainly mediates cell apoptosis [4, 5] .
Formation of Complex Ⅱ b
In some particular cases, e.g., cIAP inhibitors exist or IAPs are knocked out [6] , TAK1 inhibitors exist or TAK1 is knocked out [7] , and NEMO is knocked out [8] the MAPK pathway and NFκB pathway induced by Complex Ⅰ cannot be activated. RIPK1, RIPK3, FADD and caspase8 comprise Complex Ⅱb. Since caspase8 can break the interaction sites between RIPK1 and RIPK3, which leads to inactivation of the complex, Complex Ⅱb typically activates the RIPK1dependent apoptosis pathway rather than the necroptosis pathway mediated by the RIPK1-RIPK3 complex. Complex Ⅱb may act through the formation of necrosomes when caspase8 activity decreases or RIPK3 and mixed line age kinase like protein (MLKL) levels are high enough. Intracellular FADDlike interleukin (IL)1β converting enzyme (FLICE)inhibitory protein (FLIPL) can form caspase8FLIPL heteromeric compounds, which have only caspase8 catalytic activity. So, FLIPL participates in the regulation of both cell death pathways: apoptosis and necroptosis by controlling RIPK1 and RIPK3 level through proteolysis [4] .
Formation of Complex Ⅱ c
When caspase8 is inhibited or missing, Complex Ⅱb will transfer to Complex Ⅱc, forming necrosomes (the complex includes RIPK1, RIPK3 and MLKL). RIPK1 and RIPK3 interact and activate downstream MLKL to trigger the necroptosis pathways [4] (Figure 1 ).
Eventual executives for necroptosis
The eventual executives for necroptosis pathway are not yet clear. MLKL is one of the most widely researched molecules and a commonly used indicator assessing the effect of necroptosis in the pathogenesis of inflammatory bowel disease (IBD). MLKL is a fake kinase, which possesses a kinase domain structure but lacks kinase activity. RIPK3 can activate the corresponding threonine and serine site of MLKL and make it phosphorylate.
The phosphorylation of MLKL changes its conformation to form oligomers. Oligomerized MLKL exposes the Nterminal domain structure, which promotes necro some transfer from the cytoplasm to the cell or organelle membrane. This destroys membrane integrity and leads to cell death [9, 10] .
Other pathways for necroptosis
TNF ligand superfamily member 10 (TRAIL) and TNF ligand superfamily member 6 (FasL)mediated pathways share many similarities with the TNFα pathway, and activate caspase8 and induce apoptosis. If caspase8 is inhibited, the necroptosis pathway is activated. However, these two pathways also have their own characteristics. First, the TNFα pathway forms a prosurvival signaling complex first and then a deathinducing complex. The TRAIL/FasL pathways form a deathinducing signaling complex, which consists of Fas/DR4,5 (also known as TRAILR1,2), FADD and caspase8 [11] and subsequently induce apoptosis. Second, RIPK1 can directly bind to TNFR1 through its DD domain. The binding of FasL and TRAIL receptors to RIPK1 requires FADD as a bridge [12, 13] . Therefore, FADD is necessary for TRAIL and FasL sig naling pathways, but is not necessary for the TNFα associated pathway [11] . The main function of FADD is to provide binding sites for caspase8 and caspase10 precursors and the activated combination subsequently mediates downstream caspase3, caspase6 and caspase-7, and finally induces apoptosis [14, 15] (Figure 2 ). 747 WJCC|www.wjgnet.com
NECROPTOSIS AND INFLAMMATION
The relationship between necroptosis and inflammation remains unclear. Some scholars believe that cells release damageassociated molecular patterns (DAMPs) through pyrolysis in the process of necroptosis. DAMPs can activate the immune system by itself or combining with pathogenassociated molecular patterns. It can promote macrophages and dendritic cells and other sentinel cells activate and increase the level of abundant cytokines including interleukin (IL)1 superfamily (IL 1α, IL1β, IL18, IL33, IL36α, IL36β, and IL36γ), which mediates the pathogenesis of various acute and chronic inflammatory diseases [4, 16, 17] . Duprez et al [18] have shown that necroptosis mediated by RIPK1-RIPK3 can increase the mortality from systemic inflamma tory response syndrome induced by TNF. With RIPK3 gene knockout or preventive use of RIPK1 inhibitors, necrostain1 can effectively alleviate the levels of DAMPs in the circulation. In the model of myocardial ischemia/reperfusion, phosphorylation of RIPK1 and RIPK3 is always accompanied by infiltration of a large number of neutrophils. Necrostain1 dramatically re duces inflammation. It presents a lower level of TNF-α and oxidative stress, reduction of adverse myocardial remodeling, and improvement of cardiac function [19] . In addition, in the liver injury model induced by ethanol, the loss of RIPK3 can avoid the pathogenesis of liver cirrhosis, the increase in inflammatory factors, and therefore prevent liver tissue injury [20] . The dual deletion of RIPK1 and FADD induces necroptosis, which is dependent on RIPK3 in colon intestinal epithelial cells, decreases the number of Paneth cells, and causes localized inflammatory damage [21] . However, there are also researchers who consider that some pathogens may terminate the signaling cascade of proinflammatory factors through necroptosis to limit the cytokine storm. Necroptosis can inhibit excessive release of inflammatory factors induced by TNF/Tolllike receptor (TLR) in a specific environment and therefore plays an antiinflammatory role [16] . The TNFα pathway, for example, participates in inflam mation, apoptosis and necroptosis, but has different outcomes under disparate physiological conditions. Therefore, the result of transformation from an inflammatory response dependent on TNF to necroptosis is not just cell death (although DAMPs released during the process can also promote inflammation), but the cascade induced by TNF itself, a powerful inflammatory factor. The end of the cascade avoids stimulation of cell synthesis and the release of more cytokines and chemokines, which limit the inflammatory response [22] . According to the study of AlvarezDiaz et al [23] , mice with FADD/MLKL or caspase8/MLKL double knockout develop severe systemic autoimmune diseases and die within a short period of time due to the dramatic increase in a variety of cytokines and chemokines. In addition, Newton et al [24] have shown that RIPK3 deficiency does not improve sepsis induced by lipopolysaccharide (LPS), colitis induced by dextran sulfate sodium (DSS), pancreatitis induced by frosin, and brain injury induced by hypoxia. The absence of MLKL cannot protect again st kidney injury caused by ischemia-reperfusion [24] . 748 WJCC|www.wjgnet.com Bozec et al [25] have shown that expression of RIPK3 decreases in colorectal cancer (CRC) patients with IBD, which further demonstrate the anti-inflammatory effect of necroptosis.
NECROPTOSIS AND IBD
IBD is a kind of chronic, nonspecific intestinal inflam matory disease whose pathogenesis is unclear. The main pathological types of IBD are ulcerative colitis (UC) and Crohn's disease (CD). Despite the lack of epidemiological data for IBD in developing countries, the prevalence of IBD is on the rise globally [26] . Althou gh the cause of IBD remains unknown, environmental, infectious, immune and genetic factors are involved in the pathogenesis of excessive apoptosis of intestinal epithelial cells, damage to the intestinal mucosal barrier, and higher permeability of intestinal epithelial cells, which are considered to contribute to the development of IBD [27] . Necroptosis is a new mode of cell death. The process of necroptosis is regulated as well as apopto sis. So, some scholars think that necroptosis plays an important role in the pathogenesis of IBD.
In situ end labeling technology cannot distinguish between apoptosis and necroptosis, and early research about the effect of apoptosis in the pathogenesis of IBD cannot prove whether necroptosis plays the same role [4] . Recent studies based on animal models and patients with IBD have suggested that necroptosis plays a role in the development of intestinal inflammation.
Welz et al [28] found in mice that intestinal epithelial and severe colitis. The absence of RIPK3 or the use of CYLD inhibitors can inhibit this spontaneous pathological process. Mice with intestinal epithelial cell caspase8 gene knock out also had inflammatory lesions in the terminal ileum (increased Paneth cell death and reduced goblet cells), and high susceptibility to colitis. These findings were related to increased levels of RIPK3 [29] . RIPK3 knock down can reduce intestinal inflammation in caspase8 knockout mice to a certain extent [30] . All these studies based on mouse models have shown that necroptosis of intestinal epithelial cells induces intestinal inflammation.
Günther et al [29] have confirmed that in adult CD patients, the level of RIPK3 expressed by Paneth cells increases along with necroptosis in the terminal ileum. By comparison between adult penetration type CD patients, adult narrow type CD patients and healthy controls, serum level of TNFα and mucosal tissue level of RIPK3 are obviously increased in both types of CD [10] . Pierdomenico et al [31] investigated biopsy samples from 33 children with CD and 30 with UC and found increased expression of RIPK3 and MLKL in inflammatory tissue and dramatically decreased expression of caspase8.
There was no significant difference in expression of all three proteins in noninflammatory tissues, which confirm that necroptosis can magnify the inflammatory response and induce pathological conditions in the intestine. Negroni et al [32] have confirmed that necro ptosis induced by RIPK3 can activate MLKL and increase expression of IL8, IL1β, IL33 and highmobility group protein 1. Necroptosis then induces the translocation of NFκB p65 and the assemblage of inflammasome NLRP3. At the same time, the integrity of the intestinal epithelial barrier induced by various intercellular con nective proteins, including Cadherin E and occludin can also be influenced, which mediates the occurrence of intestinal inflammation [32] .
NECROPTOSIS AND CRC
Incoercible proliferation of intestinal epithelial cells and decreased cell death are the main pathological processes of CRC. Therefore, necroptosis plays an important role in the occurrence and development of CRC. Expression levels of RIPK1 and RIPK3 were lower in mucosal tissue of CRC patients compared to normal mucosal tissues, which indicates that necroptosis plays a role in the induction of cell death and inhibition of CRC development. Bozec et al [25] have shown that RIPK3 has a suppressive effect on CRC, while tumor cells without RIPK3 are often more invasive. RIPK3 knockout mice are more susceptible to CRC related enteritis. The lack of RIPK3 gene leads to excessive activation of the NF κB, signal transducer and activator of transcription (STAT) 3, AKT and Wntβ-catenin pathways, which results in abnormal proliferation of intestinal epithelial cells and the occurrence of tumor. The induction of TNFαrelated necroptosis by RIPK1 and NFκB can overcome the apoptosis tolerance in CRC 749 WJCC|www.wjgnet.com and significantly suppress tumor growth [33] . In vivo expe riments have confirmed that combination of a new type of pancaspase inhibitor IDN7314 and 5fluorouracil (5-FU) is beneficial in CRC patients with 5-FU resistance, through increased cell necroptosis [33] . Induction of ne croptosis also increases intestinal epithelial cell death in CRC patients with apoptosis tolerance induced by absence of caspase8 [34] . Sun et al [35] have shown that 3bromine pyruvate (hexokinase inhibitor) causes or ganelle swelling, damaged cell membrane integrity, exudation of cell contents and increased necroptosis in SW480 and HT29 colon cancer cells. Necrostin1 significantly recovers cell survival. A recent study also showed that resibufogenin suppresses growth and metastasis of CRC through RIPK3mediated necroptosis. This kind of effect can be reduced by RIPK3 deficiency rather than the use of zVAD, a pancaspase general inhibitor, which confirms the role of necroptosis in the treatment of CRC [36] .
NECROPTOSIS AND INTESTINAL
INFECTIOUS DISEASES
The balance between death and survival of intestinal epithelial cells is essential to maintain integrity of the intestinal barrier and intestinal homeostasis. Excessive death of intestinal epithelial cells damages the function of the intestinal barrier, leading to weakened resis tance to pathogenic bacteria. Hefele et al [37] have
shown that caspase8 knockout mice present with more severe mucosal injury and intestinal epithelial cell death after infection with Salmonella typhimurium compared to wildtype mice. Knock out of RIPK3 or MLKL can significantly relieve the mucosal injury and intestinal epithelial cell death. Qi et al [38] have also shown that infection with S. typhimurium without sopB induces phosphorylation of MLKL and therefore pro motes necroptosis of goblet cells. This induces more severe intestinal damage, including increased levels of cytokines and chemokines and decreased mucus and mucin2. However, this kind of physiological or pathological process can be effectively alleviated in MLKL knockout mice. TLRs expressed on the surface of intestinal epithelial cells can promote the identification of microorganisms. Stimulation of TLRs leads to intestinal epithelial cell loss, which mediates epithelial antibacterial and antiviral activity in the host and helps to remove exogenous pathogens. Caspase8 knockout mice show more severe injury of intestinal epithelial cells with the activation of the necroptosis pathway induced by RIPK3 rather than the extrinsic apoptotic pathway after stimulation of TLRs. TLR3 mediate necroptosis through TRIF and TLR4 mediates necroptosis through TNFα. RIPK inhibitor can improve intestinal injury induced by LPS and main tain the function of the intestinal barrier. These results provide new ideas for the treatment of intestinal in flammation and infectious diseases [39] (Table 1) .
DRUG THREAPY TARGETING IN NECROPTOSIS
Since necroptosis may play a partial role in the pathogenesis of IBD, regulation of the key molecules during necroptosis may provide a new target for the treatment of IBD. The most frequently studied among these is necrostatin-1, an RIPK1-specific inhibitor whose protective effect in IBD has been widely reported [29, 32, 40] . Liu et al [40] have confirmed that when the structure of RIPK1-RIPK3 complex is destroyed [41, 42] by necrostatin1, expression of RIPK1 and RIPK3 is decreased and expression of caspase8 is increased in a mouse model of intestinal inflammation induced by DSS. The use of necrostatin-1 thus restores weight loss, decreased colon length, damage to the intestinal mucosa, and excessive release of inflammatory factors like IL-6. As an effective necroptosis inhibitor, necrostatin-1 has the following characteristics: inhibition of necroptosis without affecting apoptosis and autophagy; no effect on the physiological function of normal cells [43] .
Apart from necrostatin1, autophagy protein ATG16L1 reported by MatsuzawaIshimoto et al [44] also alleviates necroptosis in an IBD model induced by virus infection, through TNFα and RIPK1, and maintains integrity of the intestinal barrier. Dong et al [45] have confirmed that necrosulfonamide reverses the histological abnormality induced by TNFα and ZVADfmk and reduces the degree of necroptosis.
Other recent studies also reported drug therapy targeting necroptosis in other diseases. Nikseresht et al [46] revealed that ex527, a selective inhibitor of Sirt1, reduced expression of critical regulators of necroptosis in a model of cerebral ischemia-reperfusion injury, which resulted in alleviation of infarction volume and increased survival.
Rats with cognitive impairment induced by severe acute pancreatitis show increased levels of RIPK3 and RIPK1, and berberine can partly treat this cognitive impairment through attenuation of neuronal necroptosis [47] . Oliveira et al [48] have found that Oxa12, a new oxazolone, can reduce TNFαinduced necroptosis in mouse L929
fibrosarcoma cells and zVAD-fmk-induced necroptosis in murine BV2 microglial cells. They have confirmed that Oxa12 disturbs the phosphorylation of MLKL and formation of necrosome complexes, which provides a new insight into the treatment of other inflammatory diseases. Another interesting study has shown that AdipoRon, an antidiabetic adiponectin receptor agonist, can lead to the death of MIAPaCa2 cells (human pancreatic carcinoma cell line) through necroptosis via the activation of RIPK1
and extracellular signalregulated kinase 1/2 [49] .
CONCLUSION
Although current research has confirmed that necroptosis is an important pathway of programmed cell death, many problems remain to be explored and resolved.
How Intestinal infectious diseases RIPK3 and MLKL upregulated when caspase-8 is deficient
(1) Impair the integrity of intestinal epithelial barrier (2) Increase levels of cytokines and chemokines, and decrease levels of mucus and mucin-2 (3) TLR-3 mediate necroptosis through TRIF and TLR-4 mediates necroptosis through TNF-α 
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terminal states also needs to be further explored.
In the necroptosis pathway, how RIPK3 induces necroptosis and inhibits apoptosis at the same time, the molecular mechanisms of MLKL, and the regulation of RIPK family activity and its substrates are still controversial. In the pathogenesis of IBD, the role of necroptosis in the process of initiation, amplification and extension of inflammation needs to be confirmed. The TNFα pathway is the most widely studied necro ptotic pathway, but which downstream effects are activated, necroptosis, apoptosis or inflammation, in the pathogenesis of IBD needs further investigation. TNF monoclonal antibody is currently the main drug for the treatment of IBD, although up to 50% of pa tients show no response, and an increased risk of infection [50] . This suggests that there is an urgent need to explore new treatments for IBD. We believe that with further investigation of the molecular mechanism of necroptosis, we will be more aware of cell death and develop new ideas for exploration of the pathogenesis of various human diseases.
